New hope for NMOSD patients: drug aims to slash relapse rate
NCT ID NCT07557420
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called ravulizumab in about 19 Chinese adults with a rare autoimmune disease called NMOSD. The goal is to see if it can reduce the number of disease attacks (relapses) and slow disability. Participants must have had at least one attack in the past year and be on stable background therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Research Site
Chengdu, 610016, China
-
Research Site
Dongguan, 523059, China
-
Research Site
Shanghai, 201107, China
-
Research Site
Wenzhou, 325000, China
-
Research Site
Wuhan, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can a simple blood test unlock the secrets of brain autoimmune diseases?
- Genetic clues may forecast multiple sclerosis after vision loss
- Engineered immune cells take aim at autoimmune diseases
- Can virtual training rewire the brain in MS?
- New study aims to understand physical challenges in kids with nerve diseases